Syqe Medical, an Israeli company, is aiming toward an IPO on the Toronto Stock Exchange, according to Israeli news source, Globes. Syqe has developed and is marking inhalers for medical cannabis that provide users with an exact dosage of CBD. The inhaler has precise control over, and the user can manage and change the dosage by an attendant monitor.
According to the company website, Syqe is a pharma-tech company developing technologies that enable the precise delivery of molecules directly from plants.
“We believe it is our responsibility to relieve the suffering of as many patients as possible in the fastest possible way, using our breakthrough technology. The Syqe platform is the first drug delivery platform in medical history to successfully administer whole plants at pharmaceutical standards.”
Perry Davidson founded and managed Syqe, and has successfully raised $50 million last year in a financing round led by Shavit Capital. The company’s products have been marketed by Israeli Pharmaceutical giant Teva since early this summer.
All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.